阿替普酶与尿激酶分别联合依诺肝素钠治疗急性ST段抬高型心肌梗死的临床观察

发布时间：2018-03-19 23:34

本文选题：阿替普酶　切入点：尿激酶　出处：《中西医结合心血管病电子杂志》2016年34期 　论文类型：期刊论文

【摘要】：目的观察阿替普酶与尿激酶分别联合依诺肝素钠对急性ST段抬高型心肌梗死治疗的临床疗效。方法我院2016年1月~2016年6月收治的68例急性ST段抬高型心肌梗死患者按照临床用药不同将所有患者均分为实验组与对照组,对照组34例患者给予尿激酶联合依诺肝素钠治疗,实验组34例患者给予阿替普酶联合依诺肝素钠治疗,比较两组患者临床治疗效果。结果实验组治疗无效率为5.9%,对照组治疗无效率为20.6%,实验组患者血管再通率、不良反应发生率以及死亡率各数据明显优于对照组,两组数据均具有统计学意义(P0.05)。结论对于急性ST段抬高型心肌梗死的患者给予阿替普酶联合依诺肝素钠能有效提高患者血管再通率,降低患者不良反应发生率和临床死亡率。
[Abstract]:Objective to observe the clinical effect of atropase and urokinase combined with enoxaparin sodium in the treatment of acute ST-segment elevation myocardial infarction. Methods from January 2016 to June 2016, 68 patients with acute ST-segment elevation myocardial infarction were treated in our hospital. All patients were divided into experimental group and control group. 34 patients in the control group were treated with urokinase combined with enoxaparin sodium, and 34 patients in the experimental group were treated with atropase combined with enoxaparin sodium. Results the ineffective rate of treatment was 5.9 in the experimental group and 20.6 in the control group. The data of vascular recanalization rate, adverse reaction rate and mortality rate in the experimental group were significantly better than those in the control group. Conclusion Atiprase combined with enoxaparin sodium in patients with acute ST-segment elevation myocardial infarction can effectively increase the rate of vascular recanalization and reduce the incidence of adverse reactions and clinical mortality in patients with acute ST-segment elevation myocardial infarction.
【作者单位】：四川省司法警官总医院;
【分类号】：R542.22

【相似文献】